accountMerck licensed the right to market Erbitux outside the US and from ImClone Systems, a whollyowned subsidiary of Eli Lilly and Company, in 1998. In , ImClone Systems, BristolMyers Squibb Company and Merck jointly develop and commercialize Erbitux. Merck...
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to Erbitux Recognized by ASCO as a 2009 Major Cancer Advance as First SCCHN Treatment to Improve Survival in 30 Years
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account